Are ECOG Scores Restricting Patient Access to Clinical Trials?
Leal Health Poster Highlights Negative Impact of Patient ECOG Scores on Clinical Trial Enrollment Eligibility at 2023 ASCO GU Cancers Symposium.
A recent poster presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium showcased the negative impact of Eastern Cooperative Oncology Group (ECOG) performance status scores on cancer patients’ eligibility to enroll in clinical trials. The poster, “ECOG score as a barrier for clinical trial eligibility in the patient population with genitourinary cancer: Is it time to adapt this criterion to real-world data?” was presented by Liat Edry-Botzer, PhD, Medical Director at Leal Health.
An ECOG score, which indicates a patient’s level of disability through a 0 to 5 scale (0 indicates a fully active patient, while 5 represents a deceased patient), is a common eligibility criterion used to assess patients for clinical trial enrollment. Pharmaceutical companies developing and executing clinical trials have historically recruited patients in relatively good physical condition (i.e., minimal comorbidities and with a favorable ECOG performance score). This is despite the fact that many cancer patients have significant disability, manifesting in higher ECOG scores and resulting in their exclusion from clinical trials.
To assess the impact of a patient's ECOG score on clinical trial eligibility, Leal analyzed ECOG performance scores for two genitourinary cancers patients (prostate and urinary bladder cancer) who used Leal’s AI-powered platform to find relevant clinical trials online. Leal adjusted the dataset to reflect a higher ECOG score per patient and discovered a significant and consistent increase in the number of trial matches. A decrease in the ECOG score from 3 to 2 resulted in a 262% and 111% increase in trial matches for prostate cancer and urinary bladder cancer patients, respectively. Additionally, among prostate and urinary bladder cancer patients reducing the ECOG score from 2 to 1 resulted in 107% and 68% percent increase in trial matches, respectively.
“Conducting trials that are weighted toward testing relatively healthy people, as opposed to including specific patient populations that these drugs are ultimately intended to treat, have a huge impact on the relevance of trial outcomes, and the drug’s safety and efficacy profile. Furthermore, if we exclude patients based on their subjective ECOG scores alone, we are excluding high potential clinical trial seekers whose ECOG score may be temporarily negatively impacted by cancer treatments.” said Edry-Botzer.
Leal Health, formerly known as Trialjectory, an AI-powered decision support platform for industry to execute patient-centric clinical trials.
Reference: Leal Health Presents Poster Highlighting Negative Impact of Patient ECOG Scores on Clinical Trial Enrollment Eligibility at 2023 ASCO GU Cancers Symposium
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
